Log in to search using one of your social media accounts:

 

Incyte stock plummets following disappointing clinical study results

Incyte Corp. ’s stock price plunged nearly 20 percent Friday after the Wilmington biotechnology company announced disappointing late-stage study results for an experimental cancer therapy. The results from a phase-III clinical study, testing Incyte’s new drug candidate epacadostat with Merck&Co. Inc. ’s immunotherapy drug Keytruda, found the combination therapy did not improve progression-free survival in patients with metastatic melanoma, a type of skin cancer. Incyte and Merck said, at…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news

Related Links:

Publication date: Available online 30 April 2018 Source:Seminars in Cancer Biology Author(s): Tobias Gutting, Elke Burgermeister, Nicolai Härtel, Matthias P. Ebert Immunotherapy is the latest revolution in cancer therapy. It continues to show impressive results in malignancies like melanoma and others. At least so far, effects are modest in colorectal cancer (CRC) and only a subset of patients benefits from already approved checkpoint inhibitors. In this review, we discuss major hurdles of immunotherapy like the immunosuppressive niche and low immunogenicity of CRC next to current achievements of checkpoint inhibitor...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
FINDINGSMelanoma, a relatively rare but deadly skin cancer, has been shown to switch differentiation states — that is, to regress to an earlier stage of development — which can lead it to become resistant to treatment. Now, UCLA researchers have found that melanomas can be divided into four distinct subtypes according to their stages of differentiation. Cell subtypes that de-differentiated — meaning that they reverted back to a less-mature cell — showed sensitivity to a type of self-inflicted cell death called ferroptosis.The research also showed that certain subtypes of melanoma cells could be succ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
SummaryImmunotherapies comprise of a  class of cancer therapies that are increasingly used for treatment of several cancer entities. Active immunotherapies encompassing immune checkpoint inhibitors are the most widespread class of immunotherapies, with indications for melanoma, non-small lung cancer, renal cell carcinoma, urothelial c arcinoma, head and neck squamous cell carcinoma, and Hodgkin’s lymphoma. Immune checkpoint inhibitors have demonstrated unique response patterns that are not adequately captured by traditional response criteria such das the Response Evaluation Criteria in Solid Tumors (RECIST) and ...
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
ConclusionsThe development of granulomatous/sarcoid-like lesions associated with CPIs is a recognized manifestation with the current class of immune checkpoint therapy that may clinically and radiographically mimic disease recurrence. Awareness of this type of toxicity is important for appropriate management and possible measurement of therapeutic response in a subset of patients who manifest this type of immune-mediated reaction.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Immunotherapy is a cut above chemotherapy and radiotherapy: at its best, it is significantly more effective and significantly less harmful to the patient. It has still required years, a great deal of funding, and many failures for those best approaches to arise. Nonetheless, the report here is a cheering example for the sizable fraction of us expected to suffer cancer at some point in the years ahead if the condition is not soon brought under medical control. This immunotherapy appears highly effective, and just importantly, adaptable to many types of cancer. This potential for broad application is the most important aspec...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
David Grimm —online news editor for Science—talks with Sarah Crespi about a long-term project monitoring raccoon latrines in California. What influence do these wild bathrooms have on the ecosystem? Sarah also interviews Christian Jobin of the University of Florida in Gainesville about his Perspective on t hree papers linking the success of cancer immunotherapy with microbes in the gut—it turns out which bacteria live in a cancer patient’s intestines can predict their response to this cutting edge cancer treatment. Read the related papers: Routy et al., Gut microbiome influences efficacy of ...
Source: Science Magazine Podcast - Category: Science Authors: Tags: Scientific Community Source Type: podcasts
Publication date: Available online 21 November 2017 Source:Seminars in Cancer Biology Author(s): K. Vermaelen, A. Waeytens, O. Kholmanskikh, M. Van den Bulcke, E. Van Valckenborgh Immunotherapies, specifically checkpoint inhibitors, are becoming an important component in cancer care with the most application now in melanoma and lung cancer patients. Some drawbacks that converge with this new evolution are the rather low response rates to these drugs and their high cost with a significant economic impact on the health care system. These major challenges can likely be circumvented by implementing a “personalized immun...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
This article is protected by copyright. All rights reserved.
Source: Muscle and Nerve - Category: Internal Medicine Authors: Tags: Invited Review Source Type: research
Authors: Hwang SJE, Fernández-Peñas P Abstract With increasing use of immunotherapies such as anti-cytotoxic T cell lymphocyte antigen-4 and anti-programmed cell death 1 antibodies, various skin toxicities have emerged. Severity of skin toxicities varies from mild lichenoid reaction to severe toxic epidermal necrolysis. Appropriate diagnosis and management of these skin toxicities are essential for optimal patient care and to avoid unnecessary cessation of anti-cancer therapies. This review summarises a wide range of cutaneous manifestations associated with immunotherapy usage in patients with metasta...
Source: Current Problems in Dermatology - Category: Dermatology Tags: Curr Probl Dermatol Source Type: research
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | Health Management | Immunotherapy | Melanoma | Merck | Skin | Skin Cancer | Study